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Abstract
Considerable attention and an enormous amount of resources have been dedicated to cancer
biomarker discovery and validation. However, there are still a limited number of useful biomarkers available for clinical use. An ideal biomarker should be easily assayed with minimally
invasive medical procedures but possess high sensitivity and specificity. Commonly used
circulating biomarkers are proteins in serum, most of which require labor-intensive analysis
hindered by low sensitivity in early tumor detection. Since the deregulation of microRNA
(miRNA) is associated with cancer development and progression, profiling of circulating
miRNAs has been used in a number of studies to identify novel minimally invasive miRNA
biomarkers. In this review, we discuss the origin of the circulating cell-free miRNAs and their
carriers in blood. We summarize the clinical use and function of potentially promising miRNA
biomarkers in a variety of different cancers, along with their downstream target genes in
tumor initiation and development. Additionally, we analyze some technical challenges in applying miRNA biomarkers to clinical practice.
Key words: serum, cancer, miRNA, biomarker.

Background
miRNAs are a class of small (18–24 nt)
non-coding regulatory RNAs that are involved in
regulating gene expression at the post-transcriptional
level. According to miRBase Release 18 (November
2011), 1,898 unique mature human miRNAs have
been identified [1] [2]. These RNA molecules regulate
numerous biological processes [3] [4], potentially up
to one third of all protein-coding genes based on
computational predictions [5]. Primary miRNA
(pri-miRNA) is cleaved by endonuclease RNase III
Dorsha in the nucleus, releasing the stem-loop
pre-miRNA [6]. Then the pre-miRNA is exported into
the cytoplasm and cleaved by endonuclease Dicer
before becoming mature miRNA, which is integrated

into the RNA-induced silencing complex (RISC) to
regulate target gene expression [7, 8]. Perfectly or
imperfectly base pairing the 3’ UTR of the target
mRNA with the 5’ end of miRNA causes genomic
instability and transcriptional degradation, as well as
translational repression [6, 9-11]. However, it is also
reported that miRNA can induce target gene overexpression [12]. The miRNA genome is often located at
fragile genomic sites which are closely related to
cancer. Their expression is deregulated due to genomic instabilities [13, 14]. We showed that the expression of the TAR miRNA protects infected cells
from apoptosis and acts by down-regulating cellular
genes involved in apoptosis [15]. The role of miRNAs
http://www.jcancer.org
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in cancer was first suspected when it was observed in
C. elegans and Drosophila that miRNAs controlled aspects of cell proliferation and apoptosis [16] [17]. Expression of various miRNAs has been reported to be
differentially altered across a variety of tumor types,
suggesting their direct involvement in oncogenesis
[18] [19] [20]. Deregulated miRNA expression profiles
were identified in many human cancers using miRNA
profiling techniques. miRNAs are associated with
embryogenesis and stem cell maintenance in mammals [21], hematopoietic stem cell differentiation [22],
and cancers [23] [24] [25]. Many studies show that
miRNA expression appears to be deregulated in cancer [26, 27].

Origin of the circulating miRNAs and their
carriers
MicroRNAs (miRNAs), a novel class of gene
regulators, have recently been studied as biomarkers
in peripheral circulation for cancer detection. However, the origin and value of these miRNAs have yet
to be elucidated. It is widely believed that the circulating miRNAs might not only come from circulating
tumor cells [28, 29], but also be released into the blood
stream directly via blood cells [30] or other tissue cells
affected by disease [31]. It is becoming clearer that the
majority circulating miRNAs are chaperoned by various carriers, such as exosomes, Ago2, HDL, etc.[32],
as carrier-free miRNAs will be degraded by RNase
digestion and other environmental factors [33-35].
However, it is still debatable whether or not miRNAs
are highly enriched in exosomes or in Arg-2 protein
complexes [36, 37], which may explain the differences
of miRNA abundance between isolating from whole
blood and from plasma or serum.
Heneghan et al. claimed that a whole blood
sample is preferable to serum and plasma for detecting miRNAs in the circulation since the concentration
of miRNAs extracted from whole blood is higher than
from serum or plasma [29]. This raises a basic concern
toward the origin of miRNAs in circulation. By sequencing miRNAs in serum and blood cells of healthy
subjects, Chen et al. noticed that most miRNAs detected in serum were almost the same type as in blood
cells [31], implying that serum miRNAs are not only
derived from primary disease sites, but also from
circulating blood cells [28]. Based on those observations, we believe using whole blood as the starting
material may increase the background signal noise in
terms of screening for disease-derived miRNAs. In the
future, for any circulating miRNA research, differentiating between cellular miRNAs and cell-free miRNAs is crucial.
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It is known that signatures of plasma/serum
miRNAs can reflect correlations to physiological or
disease conditions. LaConti et al. observed a correlation of miRNA deregulations between tissue and serum in both the KrasG12D transgenic animals and the
prostate cancer patients [38]. On the other hand, several studies demonstrated that circulating oncogenic
miRNA levels declined after tumor resection, such as
miR-21 in esophageal squamous cell carcinoma
(ESCC) [39], miR-31 in patients with oral squamous
cell carcinoma (OSCC) [40], mir-29a and mir-92 in
colorectal cancer CRC [41], miR-21 and miR-106b in
gastric cancer [42], and miRNA-195 and let-7a in breast
cancer[29]. Inversely, the levels of tumor-suppressor
miRNAs were increased, such as miR-92a/ miR638
ratio in hepatocellular carcinoma (HCC) [43]. The alteration of miRNA expression in postoperative samples, compared to preoperative ones, robustly supported the notion that specific circulating miRNAs
were from tumor cells. Furthermore, in a xenograft
mice system, relatively elevated levels of miR-629 and
miR-660 were detected in the plasma of mice xenografted with 22Rv1 cells, as compared to those of a
control group [44]. Both miR-629 and miR-660 are
expressed in 22Rv1 human prostate cancer cells and
are absent of murine homologs. Taken together, this
evidence might substantiate the claim that circulating
miRNAs could be directly derived from tumor tissues, and that the alternation of miRNAs might directly reflect the biological activity of cancers.
Exosomes. Bearing the possibility that miRNAs
secreted from tissue could be inferred by the miRNAs
from blood cells in the circulating environment, researchers are trying to find an alternative by proposing exosomes (40-100nm) as carriers of the circulating
miRNAs released by exocytosis. This model is supported by the detection of exosomes associated with
miRNAs [45-48] and vesicle encapsulated miRNAs in
serum and plasma [34, 49-51]. Exosomes are small
(50–90 nm) lipoprotein-membranous vesicles of endocytic origin, which is the fusion of multivesicular
bodies (MVB) with plasma membranes secreted into
extracellular space. Exosomes mediate cell–cell communications via ligand-receptor interaction and
transport intracellular components, including delivering miRNAs in exosomes to recipient cells by fusion
or endocytosis [52]. A variety of cells are capable of
releasing exosomes, including reticulocytes [53],
dendritic cells [54], B cells [55], T cells [56], mast cells
[57], epithelial cells [58] and tumor cells [52, 59]. Some
believe that exosomal miRNAs are secreted by a
ceramide-dependent secretory mechanism [60].
Kosaka et al. demonstrated that over-expression of
nSMase2, the rate-limiting enzyme of ceramide biohttp://www.jcancer.org
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synthesis, stimulated the secretion of exosomes as
well as an abundance of extracellular miRNA [60]. For
tumor growth and progression, these reports raised
the possibility that tumor-derived exosomal miRNAs
affect the surrounding cells through silencing tumor
suppressing gene expression [61]. On the other hand,
the inhibition of cell growth could be induced by releasing tumor suppressor miRNAs [60].
Taylor et al. first showed the presence of tumor-derived exosomes in the circulation of ovarian
cancer patients [62]. They subsequently demonstrated
that tumor-derived exosomes in circulation could be
isolated from other normal exosomes by applying
specific magnetic beads linked with a tumor-associated antibody, e.g. EpCAM, CD24 [63, 64].
By enriching tumor-derived exosomal miRNAs from
other cellular miRNAs, they observed a noteworthy
correlation between miRNAs and ovarian tumor
samples. The similarity between circulating tumor-derived exosomal miRNAs and tissue miRNAs
was also observed in paired tissue and plasma samples from patients with lung cancer [65]. However,
marker proteins that allow for the separation of tumor-derived exosomes from normal vesicles are less
defined.
HDL & LDL. Besides exosomes, Vickers et al.
found that high density lipoprotein (HDL) and light
density lipoprotein (LDL) have the capability to carry
and deliver miRNAs in plasma to distant recipient
cells [66]. Furthermore, certain miRNAs were
demonstrated to be exclusively encapsulated in either
HDL or exosomes. These findings strengthen the vesicle carrier model by introducing more microvesicles
as miRNA carriers. However, this also raises additional questions. For example, do cells choose specific
carriers for different miRNAs depending on particular bio-functions [67], regulated by different up-taking
pathways, such as endocytosis[68, 69] or membrane
fusion[70, 71]?
Ago2. Nevertheless, the vesicle carrier model itself may not be the predominant mechanism for tissue
secreted miRNAs. Some researchers surprisingly
found that the majority of circulating miRNAs are
co-fractionated with protein complexes rather than
with microvesicles in both cultured cells and human
plasma [33, 36]. They observed that most of the
miRNAs completely passed through the 0.22μm filter
but remained in the supernatant after ultracentrifugation at 110,000g, indicating most of the circulating
miRNAs are independent of exosomes or microvesicles. Furthermore, Western blotting analysis revealed
that
the
circulating
miRNAs
are
co-immunoprecipitated with anti-Ago2 antibody in a
detergent free environment [72]. This study showed
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that extracellular miRNAs are predominantly associated with the Ago2 protein (~96kDa).

Stability of the circulating miRNAs
Circulating miRNAs can be readily detected in
serum [73], plasma or whole blood [29]. Using Solexa
sequencing technology, Chen et al. detected a great
amount of small RNAs, 21-23nt length in both serum
and whole blood samples from normal individuals, as
well as patients with colorectal, non-small cell lung
cancer and diabetes [31]. Another study confirmed the
presence of small RNAs (18-24 nt) in plasma from the
total RNA extracted from human plasma using radioactive labeling method [44]. Followed by cloning and
sequencing of those small RNAs, over 93% of the sequences matched known miRNAs, and thus further
confirmed that the majority of small RNAs isolated
from plasma were indeed miRNAs. In addition, some
randomly selected miRNAs were found to be expressed consistently in both serum and plasma samples from humans, as well as in other species, such as
rats, mice, claves, bovine fetuses and horses [31].
MiRNAs are also notably stable in serum and
plasma samples [29-31, 44, 73]. Chen et al. found that
isolated serum miRNAs can survive the treatment of
RNase A, compared to other endogenous RNAs such
as 18s rRNA, 28s rRNA, GAPDH, β-actin and U6 [31].
Most serum miRNAs maintain considerable expression levels after 3 hours or overnight RNase A treatment; however large RNAs were degraded following
3 hours of RNase A treatment. Furthermore, repeat
freeze-thawing cycles [31, 73] and low/ high pH solution [31] treatments did not affect serum miRNAs.
Similarly, plasma miRNAs could remain stable in
room temperature for 24 hours and eight freeze-thaw
cycles; however, synthetic miRNAs were rapidly degraded in plasma [44]. This indicates that the endogenous plasma miRNAs in RNase-enriched circulating
system exist in a form that is resistant to plasma
RNase activity.

Circulating miRNAs as cancer biomarkers
Cancer biomarkers are used for early detection,
prognosis [29, 74] and therapeutic guidance [29, 31,
74]. An ideal biomarker should be highly specific and
sensitive with a high predictive value, which can be
detected in a rapid and simple, yet accurate and inexpensive fashion [28, 73]. Here we summarize the
use of individual miRNAs as blood-based biomarkers
and their potential biological functions in circulation.
miR-1. miR-1 in serum was found differentially
expressed in cancers, up-regulated in gastric cancer
patients [75] and down-regulated in non–small-cell
lung cancer (NSCLC) [76], as well as in primary huhttp://www.jcancer.org
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man lung tumor tissues and cell lines [77]. Ectopic
expression of miR-1 decreased migration and invasion of the A549 lung cell line and restrained cell proliferation, clonogenic survival, and anchorage-independent growth in the H1229 lung cell line.
MET (hepatocyte growth factor receptor), a receptor-type tyrosine kinase, and Pim-1, a Ser/Thr kinase
inducing tumorigenesis by promoting cell cycle progression and inhibiting apoptosis, are direct targets of
miR-1 in lung cells[77]. Additionally, in hepatocellular carcinoma[78], rhabdomyosarcoma [79], head and
neck squamous cell carcinoma (HNSCC) [80] and
bladder cancer [81], a relatively low miR-1 expression
level was observed, consistent with the effect of ectopically expressed miR-1 on tumor cell growth. Several target genes of miR-1, including MET [78], FOXP1
[78], c-Met [79] and transgelin 2 (TAGLN2) [80, 81],
were validated in these cancers.
miR-10b. Compared to healthy subjects, whole
blood miR-10b was down-regulated in colon and renal cancers as well as melanoma, but not in breast and
prostate cancers [82]. However, Heneghan et al. revealed that circulating miR-10b was higher in ER (estrogen receptor)-negative patients than in ER-positive
ones, but it cannot discriminate breast cancer from
healthy controls [29]. Serum miR-10b was significantly up-regulated in metastatic (Stage M1) breast
cancer compared to normal controls [74]. miR-10b
expression was relatively higher in micrometastatic
breast cancer cell lines BC-M1 and BC-S1 than in
breast cancer cell lines MDA-MB-231 and GI-101 [74].
The regulation of mir-10b on tumor metastasis was
observed in vitro and in vivo. Moriarty et al. discovered that exogenously expressed miR-10b in breast
cancer cell lines, SUM159PT and SUM149PT, could
repress cell migration and invasion. While
down-regulated miR-10b in T47D and MDA-MB-435
cells could induce cell migration and invasion [83].
miR-10b directly targets Tiam1 to decrease the Rac
activation, which influences cell metastasis. In another
study, Ma and colleagues found that miR-10b had
higher expression in metastatic breast cancer cell lines
than non-metastatic or normal epithelial cells [84].
Knockdown of miR-10b in metastatic breast cancer
cells inhibits invasion and migration, but not cell viability, or vice versa. Over-expression of miR-10b in
non-metastatic cell lines induces invasion and migration. Invasion and distant metastasis in breast cancer
occurred in mice when implanted with miR-10b
over-expressing cells, but not in control mice. miR-10b
directly targets and suppresses the expression and
translation of HOXD10, which functions in the inhibition of metastasis-leading gene RHOC[85].
miR-17-92 Cluster (miR-17-3p, 17-5p, miR-18,
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miR-19a, miR-19b, miR-20a, and miR-92a). In plasma,
elevated miR-17-3p and miR-17-5p levels were found
in colorectal cancer (CRC) [86] and gastric cancer (GC)
[42] respectively, but serum miR-17-5p was reduced
in non-small cell lung cancer [87]. Increased expression of miR-20a was found in the plasma of chronic
lymphocytic leukemia (CLL) patients [88] and in the
serum of individuals with gastric cancer [89].
miR-21. Differential expression of miR-21 was
reported not only in many solid tumors, but also in
hematological cancers. Over-expressed miR-21 reflects tumor malignancy and the ability of invasion
and metastasis in cells by negatively regulating several known tumor suppressor genes. Validated target
genes of miR-21 includes MARCKS [90], ANP32A
[91], SMARCA4 [91], BMPR 2 [92], PTEN [93],
ANKRD46 [94], PDCD4 [95, 96], TPM1 [97], MSH2
[98], TIMP3 [99], RASA1, TGFB1 and RASGRP1[100].
miR-21 is associated with tumor prognosis, as well as
resistance to chemotherapy. In circulation, augmented
expression of plasma miR-21 in ESCC was associated
with vascular invasion and recurrence [39]. miR-21
was highly expressed in the serum of patients with
human primary HCC [101] as well as tissue biopsy
samples and cell lines compared to normal controls
[93] [102]. Inhibition of miR-21 prohibited cell proliferation, invasion and metastasis in HCC cell lines [93].
Lawrie et al. demonstrated that miR-21 was elevated in de novo diffuse large B-cell lymphoma
(DLBCL) samples and cell lines compared to normal B
cells [103]. Serum miR-21 was expressed higher in
DLBCL than in healthy subjects [104]. Interestingly,
DLBCL patients with high levels of serum miR-21
demonstrated prolonged relapse-free survival time
[104]. This is consistent with the observation that high
miR-21 in cells is associated with better prognostic
outcome in DLBCL patients [103]. In addition, miR-21
is overexpressed in the cerebrospinal fluid (CSF) of patients with primary diffuse large B-cell lymphomas
(primary central nervous system lymphoma, PCNSL)
[105].
Serum miR-21 was expressed significantly higher in patients with hormone-refractory prostate cancer
(HRPC) than in those with localized prostate cancer,
androgen-dependent prostate cancer (ADPC) and
BPH [106]. Furthermore, serum miR-21 was elevated
in HRPC patients with chemo-resistance. The high
serum miR-21 levels found in ADPC and HRPC, but
not in localized prostate cancer patients, was associated with high serum prostate-specific antigen (PSA)
levels. The level of PSA is closely related to cancer
development and treatment response. Hence, miR-21
was believed to serve as biomarker in prostate cancer
to monitor cancer progression and treatment rehttp://www.jcancer.org
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sponses. Correspondingly, miR-21 was significantly
higher in patients with prostate cancer than normal
controls and was up-regulated in cases of metastasized prostate cancer as compared to those with localized / local advanced diseases [107]. The prostate
cancer cell lines, DU-145 and PC-3, which are less
androgen-dependent, malignant, and metastatic cells,
showed elevated miR-21 expression level [90].
Knockdown of miR-21 sensitized DU-145 and PC-3
cells to apoptosis induced by staurosporine (STS), as
well as inhibited cell invasion.
Increased serum miR-21 could distinguish patients with pancreatic ductal adenocarcinoma (PDAC)
from those with chronic pancreatitis (CP) and healthy
subjects [108]. In pancreatic MIA PaCa-2 cell lines,
miR-21 directly targets Bcl-2 gene and up-regulates
the expression of Bcl-2 [109]. Transfection with miR-21
mimic significantly restrained caspase-3 activity and
apoptosis thus enhanced cell proliferation in MIA
PaCa-2 cells. Additionally, elevated miR-21 expression accelerated the rate of cell growth under the
treatment of gemcitabine, which suggests that high
level of miR-21 diminished the chemo-sensitivity of
MIA PaCa-2 cells. Moreover, miR-21 could distinguish non-invasive precursor of PDAC, intraductal
papillary mucinous neoplasms IPMNs, [110] and the
stage Ⅲ lesions of pancreatic intraepithelial neoplasia
(PanIN) [111] from other early stage neoplasia or
normal ductal epithelium.
Plasma miR-21 was elevated in patients with
NSCLC, particularly in stage T3-4 , as compared to
normal controls, and could be used to distinguish
between tumors in stage T3-4 and in stage T1-2, but
not with lymph node metastasis and distant metastasis [112]. Similarly, the level of miR-21 was significantly higher in NSCLC tissues than in adjacent normal tissues. Also, miR-21 was lower in SCLC than in
NSCLC cell lines [113]. Knockdown of miR-21 impeded the growth of NSCLC A549 and H1703 cell
lines as well as the invasion potential of 801D cells.
miR-21 was found to be increased not only in
gastric cancer tissues and cell lines [114], but also in
plasma samples of gastric cancer as compared to
normal controls [42]. In gastric AGS cell line, forced
expression of miR-21 promotes cell proliferation, invasion and migration, but hinders apoptosis. In addition, there is an inverse correlation between RECK
and miR-21 expression in both gastric cancer tissues
and cell lines. Matrix metalloproteases (MMPs), including MMP9, MMP2, and MMP14 regulated by
RECK, are closely related to tumor metastasis [114].
Serum miR-21 is significantly increased in breast
cancer [115], especially in stage IV cancer [116]. The
level of miR-21 in matching tissue and serum was
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much greater in grade III breast cancer than in benign
tumor or ER-/PR- breast cancer [115]. In addition,
miR-21 expression was higher in breast cancer tissues
than in normal controls, especially in patients with
lymph node metastasis [99]. Inhibition of miR-21 resulted in restrained cell growth in ER+ MCF-7 cells
[94, 95] and hindered invasion and metastasis, but not
in ER- MDA-MB-231 cells [94, 117]. In mouse models,
lung metastasis was reduced when injected with the
miR-21 inhibitor-transfected MDA-MB-231 cells [117],
while tumor size in xenograft mice was decreased
when injected with miR-21 inhibitor-transfected
MCF7 cells [94].
Hormone-dependent breast cancers could be
treated by blocking the interaction between hormones
and receptors on cancer cells. The resistance of
trastuzumab, an anti-Her2 monoclonal antibody, in
Her2+ breast cancer was strongly correlated with
PTEN reduction. Gong and colleagues demonstrated
that highly expressed miR-21 in trastuzumab-resistant
Her2+ breast cancer cell lines BT474, SKBR3 and
MDA-MB-453 resulted in decreased PTEN protein
level [118]. However, the inhibition of miR-21 induced
Her2+ breast cancer cells to become sensitive to
trastuzumab via elevated expression of PTEN. In a
similar vein, miR-21 was up-regulated and PTEN
protein levels were relatively low in patients who
were resistant to trastuzumab as compared to those
sensitive to trastuzumab. Estradiol (E2) treated ER+
breast cancer MCF-7 cells significantly reduced the
expression of endogenous miR-21 [100]. On the other
hand, the all-trans-retinoic acid (ATRA) treatment, an
anti-proliferative agent, provoked the expression of
miR-21 in MCF-7 cells [119]. MCF-7 cells sensitized to
ATRA by knockdown of miR-21 displayed significant
cell growth inhibition. Another ER+ cell line, T47D,
was also sensitive to ATRA and displayed reduced
cell growth after ATRA treatment along with elevated
miR-21 levels. The inhibition of motility in MCF-7 and
T47D cells by ATRA could be lessened by ectopic
down-regulation of miR-21.
miR-24. miR-24 is highly expressed in oral
squamous cell carcinoma (OSCC) tissues, plasma and
cell lines (OC3, OECM-1 and SAS) [120], particularly,
in tongue squamous cell carcinoma (TSCC), the most
common type of OSCC [121]. DND1, which regulates
CDKN1B and subsequently controls the cell cycle,
was verified as a target gene of miR-24 in TSCC by
reporter gene assays [121].
miR-92a. In serum samples, the level of miR-92a
was increased in epithelial ovarian cancer [122].
Noteworthy were the three cases with normal
pre-operative CA-125 (< 35 U/ml) showing highly
expressed miR-92a [122], which implied that serum
http://www.jcancer.org
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miRNAs could be used as biomarkers for early detection of ovarian cancer patients with normal CA-125.
Plasma miR-92a were up-regulated in patients in
colorectal cancer (CRC) [41, 86] as well as advanced
adenomas [41] as compared to controls. Advanced
adenomas is a benign lesion with a high risk of developing into malignant CRC [123]. The early screening for advanced adenomas and precancerous lesions
could diminish the occurrence of CRC [41, 124, 125].
Therefore, circulating miR-92a could serve as a biomarker on early detection of the benign lesion, advanced adenomas, before neoplastic formation of
CRC.
Using miRNA microarray technology, Tanaka et
al. identified 148 miRNAs in normal plasma samples,
with miR-638 being the most constantly expressed
miRNA [126]. They discovered that in acute myeloid
leukemia (AML) plasma samples, the signal intensity
of miR-92a was significantly low. The ratio of miR-92a
to miR-638 in plasma was reduced in leukemia patients as compared to normal controls. The same
strategy was used to examine plasma samples of patients with HCC, which also revealed a decreased
miR-92a to miR-638 ratio, and increased after surgery
[43]. However, the expression of circulating and tissue
miR-92a was discordant in both AML/ALL and HCC.
In AML and ALL leukemic cells, miR-92a was highly
expressed. miR-92a was higher in AML and ALL cell
lines than in both CD34+ cells and peripheral blood
mononuclear cell (PBMNC) controls from healthy
volunteers [127]. Cell to plasma ratio of miR-92a expression was significantly higher in fresh ALL and
AML cells than in PBMNC cells. miR-92a showed
significantly different expression patterns in ALL.
Fresh ALL cells expressed greater miR-92a levels than
both AML and PBMNC. Furthermore, ALL patients
with three-fold or higher of miR-92a expression than
normal PBMNC cells had decreased survival rates.
Additionally, in both HCC section samples and cell
lines, Shigoka et al. found that miR-92a expression
was increased. Over-expressed miR-92a promoted cell
proliferation in HCC cell lines.
miR-122. Serum miR-122 were significantly increased in HCC as compared to normal controls, but
not as high as in hepatitis B [101]. Xu and colleagues
claimed that miR-122 might be related to liver damage, and not necessarily specific to tumor development. mir-122 is known as a liver-specific miRNA and
rich in adult liver [128]. In fact, many studies showed
that the level of miR-122 was low in HCC cell lines
and tissue samples. The anti-tumorigenic characteristics and decreased expression of miR-122 in HCC are
closely associated with tumor cell growth, invasion
and metastasis both in vivo and in vitro.
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In HCC cell lines, such as Hep3B, PLC/PRF/5,
Huh7 and SNU449, there is little to none miR-122 expression. Ectopic expression of miR-122 could drastically restrain tumor cell growth by down-regulating
the expression of CCNG1 [129] and Bcl-w [129, 130],
with reduced cell viability and increased apoptosis by
activating caspase-3 [128]. Also, it could increase
G1-phase population and inhibit tumor cell invasion,
and indirectly enhance transcriptional activity of p53
[131] in HCC cells. Potentially, miR-122 could not
only activate cell apoptosis via negatively regulating
Bcl-w but also block cell cycle progression by
down-regulating CCNG1 in HCC cells.
Overexpression of miR-122 mediated cell morphology changes and loss of actin [132], resulting in
decreased cell proliferation, colony formation and
migration [133] in various HCC cells, thus, suppressed tumor growth and neoangiogenesis in mice
models [132, 133]. Suppression of miR-122 in Huh7
cells enhanced cell proliferation, replication potential,
invasive ability and clonogenic survival. These effects
were regulated by miR-122 target genes, such as the
ADAM family genes [132, 133], which are involved in
cell adhesion, invasion and metastasis.
Tissues samples with low levels of miR-122 displayed a significant correlation between time to recurrence [131] and intrahepatic metastasis in clinical
diagnosis [132]. Relatively low levels of miR-122 in
HCC tissue samples were associated with shorter
overall survival time, larger tumor size and enhanced
cell proliferation, as well as highly expressed c-Met
and TGF-β genes [134]. This suggests that the suppression of miR-122 in HCC tumors is strongly related
to poor prognosis and aggressive tumor development.
miR-141. Plasma miR-141 was expressed higher
in colorectal cancer stage Ⅳ than in any other early
stage cases and the normal, but was not significantly
different between overall patients with CRC and
normal controls [135]. It also showed that
up-regulated plasma miR-141 was correlated to distant metastatic colon cancer and poor survival. The
combination of miR-141 and CEA improved the ability to discriminate between CRC stages. However,
Cheng et al. found that there is no significant difference between the level of miR-141 in stage Ⅳ tumor
and in early stages as well as adjacent normal tissues.
Conversely, a study discovered that miR-141 was expressed relatively lower in SW60 CRC cell line which
was derived from a metastatic site different from
other cell lines [136]. It is believed that miR-141 directed cell migration and invasion by targeting the
SIP1 gene. Smad interacting protein 1 (SIP1) is known
to suppress the expression of E-cadherin and induce
epithelial-tomesenchymal transition (EMT), which is
http://www.jcancer.org
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essential for metastasis [137, 138]. Overexpressed
miR-141 in the SW60 cell line inhibited cell migration
and invasion.
miR-141 was also expressed higher in prostate
tumor tissues than in normal tissues [139]. Serum
miR-141 was found to be increased in prostate cancer
and related to PSA level [44]. In patients diagnosed
with metastatic prostate cancer, level of miR-141 was
significantly higher than in patients with localized
advanced disease [107]. Up-regulated miR-141 was
associated with patients diagnosed with adverse risk
factors (such as high Gleason score, lymph-node involvement or distant metastasis) as miR-141 was elevated in patients with high-risk tumors with a
Gleason score ≥ 8.
miR-155. miR-155 is known as a multifunctional
microRNA which is involved in cancer development,
inflammation, immune response and hematopoietic
lineage differentiation [140]. In circulation, serum
miR-155 is decreased in epithelial ovarian cancer [122]
and NSCLC [87]. miR-155 had a relatively lower expression level in whole blood samples of prostate,
colon, renal cancer and melanoma patients than in
normal controls, except in breast cancer [82].
Plasma miR-155 increased in pancreatic ductal
adenocarcinoma (PDAC)[141] , suggesting elevated
serum miR-155 could discriminate PDAC from normal controls [108]. Likewise, miR-155 was elevated in
PDAC tissue samples and targeted the 3’-UTR of
TP53INP1 gene, which is associated with pancreatic
tumor development [142]. In the non-invasive precursor of PDAC, pancreatic intraepithelial neoplasia
(PanIN) [111] and intraductal papillary mucinous
neoplasm (IPMN) [110] lesions, miR-155 was expressed higher and further differentiated the stage of
PanIN-3 and PanIN-2 from PanIN-1 and normal ductal epithelium. High levels of miR-155 in PADC patients were related to poor survival rates [143]. It
seems that miR-155 is important in the progression of
pancreatic adenocarcinoma and could be used in early
neoplastic stage identification.
Serum miR-155 was elevated in patients with
DLBCL as compared to normal subjects [104]. The
expression of miR-155 and miR-21 were higher in
DLBCL samples than in normal peripheral blood B
cells and also higher in activated B cell-like
(ABC)-type cases compared to germinal center B
cell-like (GCB)-type cases [144-146]. In DLBCL and
Hodgkin lymphoma (HL), high levels of the
non-coding BIC gene, which serves as a primary
miRNA, are associated with an over-expression of
miR-155 [147]. miR-155 was expressed higher in HL
than in DCBCL cell lines [148].
The level of serum miR-155 was differentially
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elevated in patients with post-operatively primary
(M0) and metastasis (M1) as compared to healthy
subjects [74]. The breast cancer cell lines
MDA-MB-231, GI-101 and the micrometastatic breast
cancer cell lines BC-M1 and BC-S1 served as references to confirm the expression of chosen miRNAs in
serum. miR-155 level was higher in BC-M1 and BC-S1
cells as compared to MDA-MB-231 and GI-101 cells.
Wang and colleagues showed that miR-155 expression was higher in breast cancer tissues and matching
serums than in normal samples [115]. miR-155 in both
tissue and serum were much greater in grade Ⅲ than
in benign breast cancers. Furthermore, over-expressed
miR-155 promoted proliferation of breast cancer cell
lines and tumor growth in xenograft models [149].
Studies revealed that miR-155 was related to
chemo-sensitivity of breast cancer [150]. In BT-474
cells that expresses low levels of miR-155, ectopically
expressed miR-155 made cells become resistant to
chemotherapeutic agents such as doxorubicin, VP16,
and paclitaxel. Similarly, the suppression of miR-155
in highly endogenous miR-155 expressing HS578T
cells promoted the apoptosis ability of chemotherapeutic agents. FOXO3a was a direct target of miR-155
in breast cancer cell lines and the inverse correlation
between FOXO3a protein and miR-155 were demonstrated in both breast tumor tissues and cell lines
[150]. Due to the downstream regulation of
pro-apoptotic and growth inhibiting genes by
FOXO3a, increased miR-155 induced cell survival and
diminished miR-155 stimulated apoptosis.
miR-195. The level of whole blood miRNA-195
was greatly elevated in patients diagnosed with breast
cancer from stage I to IV, than in age-matched disease-free individuals [29]. It is suggested that circulating miRNAs could be detected during early stages
of breast cancer. In addition, the expression of
miR-195 in age- and stage-matched tumor tissues
were compared with whole blood samples [29]. In
both tumor tissues and circulation, the levels of
miR-195 were increased at progressive stages of breast
cancer, which means that miRNA-195 was expressed
higher in stage IV than in stage I or II. It reflected the
similar trend of miR-195 expression in tissue and circulation as well as the positive correlation between
tissue and circulating miR-195. Later, Heneghan and
colleagues proved that circulating miR-195 could be
used as a breast cancer specific biomarker [82]. Compared to the normal, significantly high level of
miR-195 was observed only in preoperative whole
blood samples of breast cancer, but not in other cancers, such as colon, prostate, renal and melanoma.
However, Li et al. showed that miR-195 expression was decreased in breast cancer tissues and cell
http://www.jcancer.org
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lines, and they further validated that Raf-1 and
CNND1 are direct target genes for miR-195 [151].
Another study also indicated that miR-195 was lower
in ductal carcinoma in situ (DCIS) than in normal epithelium or reduction mammoplasty [152]. Moreover,
lower expression levels of miR-195 implied the possible tumor suppressor characteristic of miR-195 in
colorectal cancer [153] as well as in hepatocellular
carcinoma [154]. Bcl2, which is known as an anti-apoptotic gene, and CCND1, CDK6 and E2F3, cell
cycle-related genes, were direct targets of miR-195 in
colorectal cancer [153] and hepatocellular carcinoma
[154] respectively. In functional analysis, transfection
of miR-195 inhibited cell growth and invasive ability,
by blocking the G1 cell cycle of tumor cells in breast
cancer and hepatocellular carcinoma [154, 155], and
inducing cell apoptosis in colorectal cancer [153].
These studies demonstrated the role of miR-195 in cell
cycle regulation and tumor development.
miR-221. Plasma miR-221 was higher in CRC
patients than in normal controls and the greater expression of miR-221 was associated with a shorter
overall survival rate [156]. Other studies that explored
miR-221 in the plasma of prostate cancer cases found
increased levels compared to controls [107, 157]. The
level of miR-221 was higher in patients with metastasized prostate cancer than in those with local advanced disease and healthy controls [107].
Similarly, miR-221 was more elevated in plasma
of Androgen-dependent (ADPC) and Androgen-independent (AIPC) prostate carcinoma than in
normal cases [157]. The level of miR-221 was higher in
plasma of ADPC than that of AIPC. miR-221 was expressed significantly higher in prostate cancer cell line
PC3 than in normal human prostate epithelial cells
RWPE-1. miR-221 down-regulated the ARHI gene by
targeting the 3’-UTR region [158]. Likewise, miR-221
was found at a comparatively higher expression level
in the androgen-independent, strongly aggressive
PC3 cell line than in the androgen-responsive 22Rv1
cells as well as in the androgen dependent, slowly
growing LNCaP cells [159]. The p27 gene, which prohibits the G1/S cell-cycle transition, was validated as
a direct target of miR-221 by reporter gene assay. After transfection, forced miR-221 could diminish the
expression of p27, therefore to promote cell proliferation, and to increase S phase population and the
number of colonies in the LNCaP cells. Transfected
anti-miR-221 in PC3 cells showed comparable effects
on colony formation: a declined colony growing in
soft agar. This indicates that miR-221 has the ability to
make prostate cancer cells more aggressive, which
could grow in an anchorage-independent way, and
promote tumor cell growth by negatively regulating
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the p27 gene.
A lower expression level of serum miR-221 was
found in NSCLC than in healthy subjects, while
miR-221 levels were higher in both NSCLC cell lines
as well as tissue samples when compared with controls
[160].
Overexpression
of
miR-221
down-regulated tumor suppressor genes PTEN and
TIMP3, and enhanced cell migration and invasive
ability in cell lines and stimulated the resistance of
TRAIL-inducing apoptosis in NSCLC cells.
miR-375. The expression of serum miR-375 was
greater in prostate cancer than in normal controls, and
greater in metastasized cancer than in primary prostate cancer [139]. Serum miR-375 increased in cases
with lymph-node positive prostate cancer and presented a close relationship between greater levels of
serum miR-375 and patients diagnosed with adverse
risk factors (high Gleason score, lymph-node involvement or distant metastasis). A microarray platform and validation by qRT-PCR revealed that
miR-375 was up-regulated in prostate tumor tissues
[161].

Method challenges in cell-free circulating
miRNA study
Serum specimens contain high volumes of protein, and therefore extraction requires a modified
protocol that adds more denaturing solution such as
Qiazol or Trizol [162]. Additionally, considering the
small amount of RNAs from serum or plasma samples, a routine spike-in synthetic non-human C.elegan
miRNA (e.g. Cel-miR-39) was used after the initial
serum denaturation step to serve as the internal quality control [163]. Another technical challenge is that
the quality metrics derived from traditional spectrophotometry might be uninformative and inaccurate
due to the low concentration of RNA from serum or
plasma. The spike-in synthetic miRNAs are therefore
important for adjusting the differences and filtering
the outliers in the samples.
Considering that profiling of circulating miRNAs are frequently confounded by cellular miRNAs,
we believe that cell-free circulating miRNAs from
exosomes will be a better starting material for profiling studies. Unfortunately, cross-contamination between cells and exosomes seem to be unavoidable.
The alternative might be to enrich exosome fractions
and eliminate cell fractions. In order to enhance the
specificity of potential circulating miRNAs, we recommend the blood plasma and serum preparation
protocol modified by Duttagupat et al.[164]. For better
targeting
the
tumor-derived
exosomes,
tumor-antibody coupled magnetic beads could be used
to enrich the tumor relevant miRNAs [165]. Once pohttp://www.jcancer.org
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tential exosomal miRNA biomarkers are identified,
they could be validated by using whole blood or unfractioned serum or plasma.
Moreover, in the assessment of whether RNA
isolation is cell-free, three main parameters should be
investigated by qPCR: i). The existence of high and
constantly expressed serum/plasma miRNAs, such as
miR-16, miR-223 or let-7a [166]. These miRNAs have
been reported to keep consistent expression levels
among plasma / serum and are correlated with the
number of blood cells. Great variance of their expression levels might indicate possible contamination
from blood cellular miRNAs. ii). The absence of typical blood cellular miRNAs, including miR-20a,
miR-106a, miR-185 and miR-144 [167]. Expression of
these miRNAs seems to be exclusive in white and red
blood cells. Positive signals for these miRNAs might
indicate that cells have lysed during the procedure.
iii). The absence of qPCR enzymatic reaction inhibitor.
Protein-rich plasma / serum could have some qPCR
inhibitors, which will distort the results and further
skew the metrics to establish a predictor system. The
presence of inhibitors means the raw Ct value will not
increase alongside an increasing RNA input. To rule
out the possibility, a standard curve of the consistently expressed miRNAs, such as spike-in miRNAs,
on a serial dilution of samples may be used.
There is no consensus right now in using endogenous reference miRNAs to normalize miRNA
qPCR results. miRNA expression levels can vary significantly depending on the tissue types, for instance,
reference miRNAs might be consistently expressed in
breast cells but aberrantly expressed in prostate cells.
Other alternative methods, including small RNAs
(most commonly used 5S, U6), total RNA, or 18S
rRNA, may not be applicable in plasma or serum
miRNA analysis. For example, 5S and U6 are not
present in plasma and serum.

Conclusions
The emergence of miRNAs as the mediator of
gene expression in carcinogenesis renders themselves
as promising potential diagnostic markers for malignancy. They are also found to be surprisingly stable in
RNase-rich serum and plasma environment, which
strengthens its feasibility as a routine clinical screening method. A number of recent studies documented
altered miRNA expression in circulation by comparing tumor patients with healthy individuals, indicating their putative role as cancer biomarkers. Also,
new models have been proposed that suggest circulating miRNAs might be released from the tumor
tissue to adjacent or distant cells in an autocrine or
paracrine manner, and this paradigm was strength-
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ened by the detection of tumor driven miRNAs in
circulating small vesicles, including exosomes and
HDL, etc. However, several issues must be addressed
before they can be validated as biomarkers for cancer.
It is challenging to avoid the interference of
blood cell miRNAs in serum/plasma miRNA profiling. Our focus is to distinguish the tumor-derived
miRNAs from those of the blood cells. Tumor-associated antigen presenting exosomes might
provide an alternative way to address this paradox.
However, limited research has been done to distinguish the efficiency of the antibody between tumor-derived exosomes and other tissue derived exosomes. In addition, other miRNA-carrying microvesicles, such as HDL, or even RNA-binding proteins like
Ago 2, broadened our knowledge of circulating
miRNAs and their transportation and delivery. More
complex questions arise, such as whether specific
miRNAs select certain carriers, or vice versa. Further
elucidation of this mechanism might allow us to tailor
particular starting materials depending on diseases.
Researchers might also argue whether or not
circulating miRNA profiling can reflect the carcinogenesis process. In other words, are the altered
miRNAs identified in circulation truly correlated to
focal tumor progression with real biological function?
Systematic validation on cells lines, human biopsy
specimens and Formalin-Fixed, Paraffin-Embedded
(FFPE) tissue might address these questions. However, if the aforementioned selective miRNA-carrier
model exists, solely whole blood or whole serum/plasma miRNA profiling studies might not be
appropriate. Nevertheless, the methodology of profiling circulating miRNAs is still challenging. For
example, the lack of a reliable endogenous miRNA
control for normalization makes it hard to evaluate
the level of miRNAs in circulation between studies
[168]. Since gene expression is known to vary within a
population, in order to obtain miRNA signatures related to diseases, it is important to determine the
range of normal variability across demographic populations [164].
It is known that the signatures of serum/plasma
miRNAs may reflect correlations to physiological or
disease conditions. Further research on how cells secrete miRNAs to extracellular environment is crucial
for targeting proper objects, which truly reflect cancer
cell carcinogenesis. It is also essential to explore direct
or indirect biological functions that circulating miRNAs may have on distant cells [61]. We expect that
study of cell-free circulating miRNAs would result in
novel molecular biomarkers for early cancer diagnosis
and management.
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Table 1. Expression of miRNAs in circulation of various cancers, along with their target genes and pathways involved.
Types of Cancer

Altered miRNAs and Regulation
in Circulation

Acute Leukemia
(AML & ALL)
Brest Cancer

Verified Target Genes in
Cells and/or Tissues

Program Predicted Pathway*

p value

↓miR-92a (plasma) [126]

Molecular Mechanisms of Cancer
Integrin Signaling
RAR activation

1.77E-22
9.78E-11
9.54E-09

↓let-7c (plasma) [28]

Molecular Mechanisms of Cancer
Wnt/β-catenin Signaling

1E-35
8.55E-18

Molecular Mechanisms of Cancer
NF-kB Signaling

1.07E-04
2.62E-04

↓let-7d (plasma) [28]
↑miR-589(plasma) [28]
↑miR-425 (plasma) [28]
↑miR-21 (serum) [115, 116]

PTEN [118],PDCD4 [100, 117,
169-171], RTN4, NCAPG,
DERL1, PLOD3, BASP1 [171],
Maspin [117], RASA1,
TGFB1,RASGRP1 [100],
ANKRD46 [94], MSH2 [98],
ICAM-1,PLAT,IL1B[119],
TIMP3 [99], TPM1[97]

Molecular Mechanisms of Cancer
TGF-β Signaling
Wnt/β-catenin Signaling
PTEN Signaling

1.11E-19
6.68E-09
8.35E-07
9.96E-07

↑miR-34a (serum) [74]

Axl [172]

Molecular Mechanism of Cancer
ERK/MARK Signaling
Wnt/β-catenin Signaling
PI3k/AKT Signaling

1.13E-41
1.38E-35
1.04E-20
6.42E-20

ERK/MARK Signaling
PTEN Signaling

2.26E-19
2.44E-18

PDGF signaling

6.67E-05

Molecular Mechanisms of Cancer
Role of BRCA1in DNA Damage Response

4.71E-04
1.7E-03

Molecular Mechanisms of Cancer
PTEN Signaling
PI3K/AKT Signaling
Wnt/β-catenin Signaling

6.15E-33
2.87E-23
1.52E-19
3.07E-19

↑miR-29a (plasma) [41]

Molecular Mechanisms of Cancer
IL-8 Signaling
VEGF Signaling

1.8E-21
2.84E-14
4.64E-12

↑miR-92a (plasma) [174] [41]

Integrin Signaling
RAR Activation

9.78E-11
9.54E-09

GNRH Signaling
Wnt/β-catenin Signaling

1.29E-15
1.87E-12

ERK/MAPK Signaling
p53 Signaling
PTEN Signaling

9.49E-10
4.04E-8
1.07E-7

G1/S checkpoint regulation
Integrin Signaling

8.75E-07
6.05E-06

↑miR-106a (serum) [115]
↓miR-126 (serum) [115]

IRS-1 [173]

↑miR-155 (serum) [74, 115]

SOCS1 [149], FOXO3a [150]

↓miR-199a (serum) [115]
↓miR-335 (serum) [115]

↑miR-195 (whole blood)[29, 82]

CCND1 [27]

↑let-7a (whole blood)[29, 82]
Chronic Lymphocytic Leukemia
(CLL)

↑miR-195 (plasma) [88]

Colorectal Cancer
(CRC)

↑miR-17-3p (plasma) [174]

↑miR-141 (plasma) [135]

SIP1 [136]

↑miR-221 (plasma) [156]

↑let-7a (whole blood) [82]
↓miR-10b (whole blood) [82]
↓miR-155 (whole blood) [82]
Diffuse Large B-Cell ↑miR-21 (serum) [104]
Lymphoma
↑miR-155 (serum) [104]

SMAD5 [175], SHIP1[146],
AGTR1,FGF7,ZNF537,ZIC3
AND IKBKE [176]
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↑miR-210 (serum) [104]
Epithelial Ovarian
Cancer

↑miR-21 (serum) [122]
↑miR-29a (serum) [122]
↑miR-92a (serum) [122]
↑miR-93 (serum) [122]
↑miR-99b (serum) [122]

PTEN Signaling

1.95E-05

Growth Hormone Signaling
Prolactin Signaling
VDR/RXR Activation

1.15E-06
1.53E-06
2E-06

p53 Signaling

3.59E-12

↑miR-133a (serum) [177]

Wnt/β-catenin signaling
ERK/MAPK Signaling
PTEN Signaling

2.81E-13
2.29E-11
2.64E-09

↑miR-148a (serum) [177]

ERK/MAPK Signaling

4.11E-15

↑miR-223 (serum) [177]

IGF-1 Signaling
PTEN Signaling

2.53E-13
1.82E-09

ERK/MAPK Signaling
PTEN Signaling

2.64E-17
1.54E-16

PTEN Signaling
PPARα/RXRα activation
PAK Signaling

4.26E-20
1.09E-19
2.9E-15

PTEN Signaling

3.19E-04

Protein Kinase A signaling
Thrombin Signaling
Phospholipase C Signaling

1.04E-05
1.05E-04
1.84E-04

↑miR-126 (serum) [122]
↓miR-127 (serum) [122]
↓miR-155 (serum )[122]
Esophageal Squamous Cell Carcinoma (ESCC)

↑miR-21 (plasma) [39]
↓miR-375 (plasma) [39]

↑miR-10a (serum) [177]
↑miR-22 (serum) [177]
↑miR-100 (serum) [177]
↑miR-127-3p (serum) [177]

Gastric Cancer (GC) ↑miR-17-5p (plasma) [42]
↑miR-21 (plasma) [42]

RECK [114]

↑miR-106a (plasma) [42]
↑miR-106b (plasma) [42]
↓let-7a (plasma) [42]

RAB40C[178]

↑miR-1 (serum) [179]
↑miR-34a (serum) [179]
↑miR-20 (serum) [179]
↑miR-27a (serum) [179]

Hepatocellular Car- ↓miR-92a (plasma) [43]
cinoma (HCC)
↑miR-21 (serum) [101]

Prohibitin [180]

PTEN [93], RHOB [102]

↑miR-122 (serum) [101]

Bcl-w [128]

↑miR-223 (serum) [101]

STMN1 [181], SLC7A1, AKT3,
ADAM17 [132], CUTL1
[182],CCNG1[130],
ADAM10,SRF,IGF1R[133]

↑miR-500 (serum) [183]
↑miR-885-5p (serum) [184]

Melanoma

↓miR-10b (whole blood) [82]
↓miR-155 (whole blood) [82]

Non-small Cell
Lung Cancer
(NSCLC)

↓miR-20b (plasma) [185]
↑miR-21 (plasma) [112]

PTEN [186]

↓miR-30e-3p (plasma) [185]
↓let-7f (plasma) [185]
↓miR-1 (serum) [187]

MET, Pim-1[77]

↓miR-17-5p (serum) [87]
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↑miR-25 (serum) [31]
↓miR-27a (serum) [87]
↑miR-29c (serum) [87]
↑miR-30d (serum) [87]

Wnt/β-catenin Signaling
PTEN Signaling
Integrin Signaling
PI3K/AKT Signaling

9.15E-20
6.19E-18
3.98E-17
5.55E-16

PPAR Signaling
RAR Activation

7.15E-06
7.98E-05

↑miR-486 (serum) [187]

IGF-1 Signaling
PI3k/AKT Signaling

1.12E-05
2.2E-05

↓miR-499 (serum) [187]

Wnt/β-catenin Signaling

1.65E-15

↓miR-106a (serum) [87]
↓miR-146 (serum) [87]
↓miR-155 (serum) [87]
↓miR-221 (serum) [87]

PTEN, TIMP3 [160]

↑miR-223 (serum) [31]

↓let-7a (serum, whole blood) [87]
[188]

NIRF [189]

Oral Squamous Cell ↑miR-24 (plasma) [120]
Carcinoma (OSCC) ↑miR-31 (plasma) [40]

DND1 [120]

PTEN Signaling

9E-14

FIH [99]

Thrombin Signaling
ERK/MAPK Signaling

3.36E-09
7.9E-08

Pancreatic Cancer

↑miR-21 (plasma) [141] (serum)
[108]

Bcl-2 [109]

↑miR-155 (plasma)[141]

TP53INP1 [142]
G1/S checkpoint regulation

5.69E-07

ERK/MAPK Signaling
Wnt/β-catenin Signaling
PI3K/AKT Signaling

1.38E-35
1.04E-20
6.42E-20

↑miR-196a (plasma) (serum)[141]
↑miR-210 (plasma) [190]

EFNA3 [143]

↑miR-155 (serum) [141]
↑miR-200a (serum) [191]
↑miR-200b (serum) [191]

Prostate Cancer

↑miR-21 (plasma) [107]

ANP32A, SMARCA4[91]
BMPR2[92], MARCKS[90]

↑miR-141 (plasma) [107] (serum)
[192] [44]
↑miR-221 (plasma) [107] [157]

p27kip1 [159], ARHI [158]

↑miR-375 (serum) [192]

Sec23A [193]

↑let-7a (whole blood) [82]
↓miR-155 (whole blood) [82]
Rhabdomyosarcoma ↑miR-206 [194]
(RMS)
Tongue Squamous
Cell Carcinoma
(TSCC)

↑miR-184 [195]
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